Are ARTV insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ARTV leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / ARTV / insiders

PALI (32) PLX (23) DTIL (30) IKT (29) ⌘ Pro Terminal →

Artiva Biotherapeutics Inc. (ARTV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is ARTV trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTV last traded at $4.19 (0.00% on volume of 938,360 shares), positioning the stock -47.49% below its 50-day simple moving average ($7.98) and -47.76% below its 200-day simple moving average ($8.02). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.4% ($3.67 to $4.71).

$4.19 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.18

Artiva Biotherapeutics Inc. (ARTV) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $204.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARTV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $4.19 (0.00% 1D, market cap $204.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #888 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARTV compare to PALI and PLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M) and PLX (Protalix BioTherapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M). Among the 5-stock peer group, ARTV leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARTV?

▼

Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $251.5M in revenue (+100086.5% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.18 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARTV)Realized 20D OHLCV Swing Band: ±12.4%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY ARTV SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+9/20 pts (33% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 20.7 (OVERSOLD (<32))

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (26% of score)

Altman Z-Score 1.03 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.77-13% Next Q

Q2 (-2Q)

Grade E$5.89+4.6% Next Q

Q3 (-1Q)

Grade E$6.16-32% Next Q

Current

Grade E$4.19-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARTV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARTV currently carries a cautious 27/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.98) and Max Pain ($4.40) forces dealer call-delta covering toward $15.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARTV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARTV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ARTV Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ARTV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ARTV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARTV)

✓Walkthrough of ARTV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARTV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.89%🛡️ HOLDING TREND SUPPORT

2026-11-03O $4.23H $4.23L $4.19C $4.19VOL 1.97M

RES: $11.54SUP: $3.73SMA50: $7.98SMA200: $8.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARTV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARTV Butterfly Map → + Track ARTV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARTV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARTV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARTV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARTV)

Health Care Rank #888 of 1016 ⚔️ PALI vs ARTV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARTV vs. PALI, PLX, DTIL, IKT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artiva Biotherapeutics Inc. (ARTV) ranks #888 by composite RQD confidence (27/100, grade E) and #570 by equity capitalization ($204.8M). Within this direct 5-issuer industry benchmark cohort, ARTV leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. PALI currently holds the highest overall quantitative score in the immediate peer group at 32/100 (E) compared with ARTV at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARTV ACTIVE Artiva Biotherapeutics Inc.	E	27/100	—	—	-35.0%	0.00%	$204.8M	Benchmark Subject
PALI Palisade Bio Inc.	E	32/100	—	—	-35.0%	-3.45%	$202.2M	/pali-vs-artv →
PLX Protalix BioTherapeutics Inc.	E	23/100	—	48.8%	-13.0%	-1.16%	$208.7M	/plx-vs-artv →
DTIL Precision BioSciences Inc.	E	30/100	—	—	-35.0%	-1.56%	$194.9M	/dtil-vs-artv →
IKT Inhibikase Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.64%	$216.3M	/ikt-vs-artv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817241

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artiva Biotherapeutics Inc. (ARTV) reported GAAP revenue of $251.5M (+100086.5% vs. FY2024 revenue of $251.0K , and +663.8% cumulative change since FY2023) , GAAP net income of -$83.9M, operating cash flow of -$76.8M, and free cash flow of -$79.3M (-42.5% YoY). On the balance sheet, ARTV closed FY2025 with $130.9M in total assets against $0 in total debt (Altman Z-Score: 1.03, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$251.5M	-$83.9M	-$76.8M	-$79.3M	$130.9M	—
FY2024 (FY)	2024-12-31	$251.0K	-$65.4M	-$55.0M	-$55.7M	$209.6M	—
FY2023 (FY)	2023-12-31	$32.9M	-$28.7M	-$47.4M	-$47.4M	—	—

3. ARTV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARTV compare to PALI and PLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARTV?

Where is ARTV trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTV last traded at $4.19 (0.00% on volume of 938,360 shares), positioning the stock -47.49% below its 50-day simple moving average ($7.98) and -47.76% below its 200-day simple moving average ($8.02). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.4% ($3.67 to $4.71).

Direct Sub-Reports: ARTV RQD Cockpit ARTV 12M Forecast ARTV Earnings & Move ARTV Dividends & DRIP ARTV Insiders & 13F ARTV Whale Options ARTV Profit Sankey ARTV News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARTV — Artiva Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:59Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ARTV carries an RQD Score of 39 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 3 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. The company reported no revenue in FY 2025 and an FCF of -$79.3M, so the cash-generation pillar is at its floor.
Whale 13F Flow: 9 / 20. The rating labels this pillar as institutional accumulation and options positioning. The source data contains no 13F holder detail (see Analyst View section), so the basis for this score cannot be verified from the provided material. Investors should treat this pillar as lower-confidence than the financial pillars.
Insider Conviction: 5 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow.
Macro Regime Fit: 15 / 20. The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market; for a loss-making biotech, that market sensitivity sits alongside company-specific risk that beta does not capture.
Forensic Balance Sheet: 7 / 20. The rating cites an Altman Z-Score of 1.03, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. A low Altman Z and Piotroski score point to elevated financial distress and weak fundamental quality. Investors should weigh this pillar heavily, since it bears directly on solvency and dilution risk.

Investor implications: The combined rating points to a vulnerable balance sheet and weak cash flow. The sharpest upside driver would be a demonstrated clinical or commercial catalyst that restores investor confidence, but the recent news flow (Section: Recent Catalysts) points in the opposite direction. Valuation tradeoffs are significant: with no reported earnings and a negative ROIC, conventional earnings multiples cannot be computed from the source data.

2. Business Model, Unit Margins & SEC Financial Trajectory

Artiva Biotherapeutics Inc. (ARTV) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry..2B. Per the Financial Trend data, reported revenue fell from $32.9M in FY 2023 to $0.

The company reported operating losses in each period shown, with net losses of -$83.9M in FY 2025 and -$65.4M in FY 2024. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the forensic balance sheet inputs in the RQD rating, the Altman Z-Score is 1.03, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $40.2M in FY 2024 to $26.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The stock trades near its 52-week low at $4.19 against a $206.8M market cap, leaving room for a recovery if a future catalyst emerges. With Fundamental Cash Engine at 3/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $2.96 – $14.53 52-week range.
🐻 Primary Bear Case: Negative FY 2025 FCF of -$79.3M against $26.7M of reported cash, a 1.03 Altman Z-Score, and news of a 94% workforce cut point to acute solvency and funding risk. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links, supply-chain dependencies, or proprietary signals are mapped for ARTV. Sector and industry classification (Health Care; Biological Products) are the only structural data available. Investors should monitor whether reported cash of $26.7M (FY 2025) is sufficient relative to the FY 2025 FCF of -$79.

Key Question #1: What is the company's cash runway given reported cash of $26.7M against FY 2025 FCF of -$79.3M?
Key Question #2: What specific therapy programs were discontinued, and what is the remaining pipeline?
Key Question #3: What drove the revenue decline from $32.9M in FY 2023 to — in FY 2025?

ARTV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Artiva Biotherapeutics Inc. (ARTV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARTV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Australia • 20h ago

Artiva Biotherapeutics, Inc. (ARTV) stock price, news, quote and history

Yahoo Finance Australia report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 23h ago

Artiva stock down after discontinuing lead asset (ARTV:NASDAQ)

Seeking Alpha report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Why Is Artiva Biotherapeutics Stock Tumbling Today? - Artiva Biotherapeutics (NASDAQ:ARTV)

Benzinga report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Artiva Biotherapeutics stock tumbles after halting drug trial

Investing.com report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Artiva Biotherapeutics (NasdaqGM:ARTV) Stock Forecast & Analyst Predictions

Simply Wall St report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

About 94% of Artiva’s workforce is being cut as it ends therapy development.

Stock Titan report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

ARTV Stock Holds Support As Cash Runway Draws Trader Focus

StocksToTrade report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Artiva Biotherapeutics Shares Fall After Announcing Plan to End AlloNK Development, Analyst Downgrades

Yahoo Finance report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARTV Bull vs. Bear Conversation Board — What's Your Call at $4.19?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARTV 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH 🎯 Target: $4.86 (+16.0%)

📌 Pinned Debate

The stock trades near its 52-week low at $4.19 against a $206.8M market cap, leaving room for a recovery if a future catalyst emerges.

Picked up a starter position in ARTV in my $100K Virtual Cash book at $4.19. The stock trades near its 52-week low at $4.19 against a $206.8M market cap, leaving room for a recovery if a future catalyst emerges.. Trading inside a $2.96–$14.53 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan Forensic Short Bias 🐻 BEARISH 🎯 Target: $3.56 (-15.0%)

Spot @ $4.19

Negative FY 2025 FCF of -$79.3M against $26.7M of reported cash, a 1.03 Altman Z-Score, and news of a 94% workforce cut point to acute

Here is the bear case nobody on the bull side wants to address on ARTV: Negative FY 2025 FCF of -$79.3M against $26.7M of reported cash, a 1.03 Altman Z-Score, and news of a 94% workforce cut point to acute solvency and funding risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.